Pike County native Andrew Bauer to lead Adena Pike Medical Center

WAVERLY, Ohio, May 15, 2025 /PRNewswire/ -- Adena Health today announced the appointment of Andrew Bauer as the new senior operations executive officer of Adena Pike Medical Center and the health system's vice president of its east and south regions, effective September 1, 2025. Bauer succeeds Dave Zanni, who will retire at the end of August after more than a decade of transformational leadership at the critical access hospital.
Bauer, a Pike County native with deep community ties, currently serves as Director of Operations at Adena Pike Medical Center, a role he was hired into by Zanni. Their close professional relationship has paved the way for a seamless transition.
'Dave has been here since Adena Pike Medical Center became part of the Adena Health family and has built an incredible momentum,' Bauer said. 'I'm honored to carry that torch forward.'
Zanni, who has served in his role since 2014, has been instrumental in expanding services and upgrading facilities, helping Adena Pike Medical Center become a vital hub of care in Pike County and the surrounding communities. Throughout that transformation, Bauer has been a key partner in driving progress and shaping the hospital's future.
'Andrew is an exceptional leader who takes on challenges with both grace and energy,' Zanni said. 'His intelligence, commitment to our mission, and deep understanding of this community make him the ideal person to lead this hospital.'
Under Zanni's guidance, Adena Pike Medical Center grew its capabilities significantly, particularly during the COVID-19 pandemic when the hospital demonstrated its ability to care for patients with more complex conditions. Today, nearly 20 specialists rotate through the hospital in areas such as behavioral health, cardiology, dermatology, endoscopy, general surgery, nephrology, neurology, obstetrics, pain management, podiatry, and sports medicine.
Bauer is committed to further expanding access to specialty care and raising awareness of available services throughout the region.
'We've laid the groundwork for exciting growth,' Bauer said. 'With increasing support from our Adena Medical Group partners, we're opening doors for both clinical and operational expansion across Pike County and beyond.'
Adena Chief Operating Officer Kathi Edrington praised Bauer's track record and leadership.
'This reflects the strength of our internal talent, as well as our continued commitment to regional growth and excellence in care,' Edrington said. 'Andrew has played a key role in the hospital's transformation, and his strong operational leadership and local roots will serve the community well.'
A graduate of Western High School, Bauer and his family live in Piketon, where his children attend school. His wife, Victoria, is also a caregiver at Adena Family Medicine – Piketon.
'Dave built a strong foundation,' Bauer added. 'Now it's my turn to take us even further because our patients, staff, and community deserve nothing less.'
Learn more about the expert providers, specialty services, and patient care available at Adena Pike Medical Center by visiting Adena.org/APMC.
Adena Health
Adena Health is an independent, not-for-profit health care system committed to its mission of being 'called to serve our communities.' For more than 125 years, Adena has provided high quality, compassionate care to more than 368,000 residents across nine counties in south central and southern Ohio. The organization operates four hospitals with a total of 341 beds and employs over 3,300 individuals, including more than 400 physicians and advanced practice providers, through a network of over 40 locations. Adena offers a full range of services, including emergency and urgent care, primary and specialty care, and advanced specialties in orthopedics and sports medicine, heart and vascular care, oncology, pediatrics, and women's health. For more information, visit Adena.org.
View original content: https://www.prnewswire.com/news-releases/pike-county-native-andrew-bauer-to-lead-adena-pike-medical-center-302456827.html
SOURCE Adena Health

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

The Hill

3 hours ago

• The Hill

New COVID variant causes ‘razor blade throat'

Patients and doctors say the latest COVID-19 variant spreading in the U.S. in some cases causes a sore throat so painful it has earned the nickname 'razor blade throat.' The 'Nimbus' variant, which is officially known as NB.1.8.1., is a descendant of the Omicron is currently being monitored by the World Health Organization. 'Your throat is so dry, so cracked, it's so painful, it's even hard to drink sometimes,' Muhammad Azam, a physician with Sharp Community Medical Group in California, told ABC 10. The variant was first identified in January. It has since been found around the globe, including in Canada and at least 13 states in the U.S. Apart from 'razor blade throat,' it causes symptoms similar to other Omicron variants of the virus, like cough, fever, fatigue, muscle aches, congestion, headache, nausea, vomiting and loss of smell or taste, according to the Centers for Disease Control and Prevention. 'Sore throat has been a part of the spectrum of COVID from the beginning,' said Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security. 'It is something that we know occurs just like it occurs with many other respiratory viruses.' Most cases of COVID-19 in the U.S. are still caused by the LP.8.1. strain, but the NB.1.8.1 variant is becoming increasingly prominent. According to CDC data, 38 percent of COVID cases stem from the LP.8.1 strain while 37 percent of COVID cases now stem from the 'Nimbus' variant. The agency notes on its website that, given the low number of virus sequences being reported, its precision is low. NB.1.8.1 does not appear to be any more of a global threat than other variants, according to the WHO. The organization also said that the existing COVID-19 vaccines provide adequate protection against severe illness and hospitalization caused by the new variant. Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco, told ABC News that most COVID patients are reporting sore throat. 'I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum,' he said.

New York Post

5 hours ago

• New York Post

Sewage lines: Cape Cod summer hotspot testing its waste for cocaine and other drugs to monitor abuse

That's a crap load of partying! A summertime island hotspot off Cape Cod will start testing its sewage for cocaine and other drugs to find out when and how often residents are getting high, officials said. Nantucket health officials want to sniff out when drug use spikes — including seasonally and around holidays — to help folks with recovery outreach in the scenic town, the Nantucket Current reported. Advertisement 'Everyone's got a good idea of what the [drug] situation is, but we have very little direct measurement,' the town's human services director, Jerico Mele, told the outlet. 'When we get away from our gut to getting data, we get a better picture of what's going on.' Nantucket will start testing its sewage for cocaine and other drugs to find out when and how often residents are getting high, officials said. Naya Na – Biobot, a firm that specializes in wastewater epidemiology, will start testing the island's Surfside Wastewater Treatment Facility for drugs — also including fentanyl, opiates, methamphetamine and nicotine — later this month, according to the report. Advertisement The goal is to potentially team up with drug rehab centers and medical providers to help local addicts based on the results, Mele said. 'If we can get an idea of the standard usage of drugs, we can see if interventions and behaviors change the rate of consumption,' Mele said. 'That can give us a scorecard on the efforts and reducing usage.' The data gathering project is Nantucket's, well, number two in the world of sewage: In 2020, it started testing its wastewater for COVID-19 and still does weekly. Nantucket officials said the drug data gathering project will help with recovery outreach. Kevin – Advertisement Officials don't plan to post the new drug testing results publicly but may share them with healthcare partners, they said. It's unclear if the windswept island destination, which has a year-round population of roughly 14,000, currently has a drug use problem. A report from the National Drug Intelligence Center from 2001 named cocaine — specifically crack— as the biggest drug threat for Nantucket and surrounding areas.